SciTech Development Announces the Closing of Oversubscribed $5.5 Million Funding Round to Continue Cancer Clinical Trials
SciTech Development Announces the Closing of Oversubscribed $5.5 Million Funding Round to Continue Cancer Clinical Trials NEWS PROVIDED BY SciTech Development, Inc. Sep 24, 2025, 09:00 ET Investor confidence is fueled by remarkable interim clinical trial results for its drug, ST-001 nanoFenretinide™, showing 100% disease control at higher dose levels. DETROIT, Sept. 24, 2025…